amplicon sequencing reinvented

CleanPlex® is the most advanced targeted amplicon sequencing technology for precision medicine and research.

With over 400 custom NGS panels delivered, Paragon Genomics strives to be your NGS assay partner of choice. 

NGS Assays


Solid Tumor Profiling

Tumor profiling using NGS targeted sequencing

Infectious Disease

infectious disease research and testing, pathogen detection via NGS targeted amplicon sequencing

cfDNA Analysis

cancer liquid biopsy via NGS targeted sequencing

CTC Analysis

single cell circulating tumor cells analysis via NGS targeted sequencing

Genetic Disorders

inherited diseases and genetic disorders research via NGS targeted amplicon sequencing


pharmacogenomics or pharmacogenetics research and testing via NGS targeted amplicon sequencing


crispr editing confirmation and off-target evaluation via NGS targeted amplicon sequencing

Molecular Breeding

agrigenomics and molecular breeding via NGS targeted amplicon sequencing

Customer Testimonials

Affordable and easy-to-use product

“When we decided to choose a target enrichment platform, we had several choices and I am delighted that we chose Paragon Genomics. Paragon Genomics has enabled us to move our sequencing in-house with an affordable and easy-to-use product. They assisted us every step along the way from choosing the amplicons, to guiding us through library preparation to assisting with analysis. I strongly recommend their CleanPlex® amplicon-based targeted sequencing approach and could not be happier with their product.”

Elliot Stieglitz, MD, Assistant Professor, University of California San Francisco

Complete viral genomes from clinical samples with low viral content

“We’re using Paragon’s CleanPlex and CleanPlex UMI technologies to sequence RNA viruses. These technologies enable us to rapidly and cost-effectively obtain complete viral genomes from clinical samples with low viral content. Further analyses of viral genomes, including the identification of minor variants, elucidates viral diversity and evolution. Paragon has enthusiastically worked with us to tackle this new application; they have diligently designed panels to our specifications, meeting with us frequently to optimize the design.”

Aaron Lin, PhD; Erica Normandin; Kim Lagerborg, The Broad Institute of MIT and Harvard

Great PCR uniformity and on-target rate

“Paragon Genomics designed a high-quality NGS custom panel for us within two weeks. Its CleanPlex® targeted library technology is fast and easy to use with great PCR uniformity and on-target rate. We are very satisfied by CleanPlex product performance and the superb technical and customer support provided by the Company.”

Chongjian Chen, PhD, CEO, Annoroad

Robust and work directly from the start

“As a service provider and distributor company, it is crucial for us to fulfill inquiries coming from our customer in a fast and reliable manner. Paragon Genomics’ custom design and production pipeline has shown itself very useful to expand our portfolio and services in a very short time. Their CleanPlex® assays are robust and work directly from the start with a uniform coverage distribution and the ability to design single gene or small gene panels as well as larger panels makes CleanPlex a flexible tool.”

Damla Erdogan, Business Development Manager, Gen Era Diagnostics

A ‘future proof method’ and a ‘one and done’ approach

“We are looking for a ‘future proof method’, a better way to do high throughput screening at a species level diagnosis. Paragon Genomics has developed a rapid 2.5-hour library preparation allowing multi-gene methodology, letting us look at lots of unique loci across multiple genomes. It offers a ‘one and done’ approach instead of many different disconnected experiments.”

Scott Geib, PhD, Research Entomologist, USDA-ARS

Who’s Choosing CleanPlex NGS Panels

Researchers and assay developers from over 200 research, testing, IVD and biopharma organizations globally are using CleanPlex for their targeted sequencing applications

For early access to our upcoming Respiratory Research Panel combining Influenza A/B and SARS-CoV-2 testing, please visit HERE. Dismiss